MSc. Marek Borský

Date of birth: 1th October 1973

Education, qualification:

1997 – MSc. in Molecular biology, Faculty of Science, Masaryk University Brno
2008 - postgraduate exam – Investigative Methods in Clinical Hematology (attestation)

Positions:

1997 - 2002 researcher, Research Institute of Child Health Brno
2002 - to date, researcher, Centre of Molecular Biology and Gene Therapy, Dept. of. Internal Medicine – Hematology and Oncology, University Hospital Brno
2011 – to date, head of Laboratory of flow cytometry, Centre of Molecular Biology and Genetics, Dept. of. Internal Medicine – Hematology and Oncology, University Hospital Brno

Societies membership:

Czech Society for Analytical Cytology
Czech Society of Haematology CzMA

Selected publications (2016- 2021):

1. Sharma S, Pavlasova GM, Seda V, et al. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. *Blood*. 2021;137(18):2481-2494. doi:10.1182/blood.2020005627
2. Seda V, Vojackova E, Ondrisova L, et al. FoxO1-GAB1 Axis Regulates Homing Capacity and Tonic AKT Activity in Chronic Lymphocytic Leukemia [published online ahead of print, 2021 Mar 30]. *Blood*. 2021;blood.2020008101. doi:10.1182/blood.2020008101
3. Boudny M, Zemanova J, Khirsariya P, et al. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells. *Haematologica*. 2019;104(12):2443-2455. doi:10.3324/haematol.2018.203430
4. Pavlasova G, Borsky M, Svobodova V, et al. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. *Leukemia*. 2018;32(9):2028-2031. doi:10.1038/s41375-018-0211-0
5. Brazdilova K, Plevova K, Skuhrova Francova H, et al. Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL. *Leukemia*. 2018;32(1):234-236. doi:10.1038/leu.2017.274
6. Kantorova B, Malcikova J, Brazdilova K, et al. Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients. *Br J Haematol*. 2017;178(6):979-982. doi:10.1111/bjh.14176
7. Zemanova J, Hylse O, Collakova J, et al. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells. *Oncotarget*. 2016;7(38):62091-62106. doi:10.18632/oncotarget.11388
8. Pavlasova G, Borsky M, Seda V, et al. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. *Blood*. 2016;128(12):1609-1613. doi:10.1182/blood-2016-04-709519
9. Culen M, Borsky M, Nemethova V, et al. Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects. *Oncotarget*. 2016;7(22):33016-33024. doi:10.18632/oncotarget.9108

10. Poppova L, Janovska P, Plevova K, et al. Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV. *Br J Haematol*. 2016;175(5):851-859. doi:10.1111/bjh.14312

1.5.2021